ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ONT Oxford Nanopore Technologies Plc

135.00
2.80 (2.12%)
Last Updated: 13:18:48
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Nanopore Technologies Plc LSE:ONT London Ordinary Share GB00BP6S8Z30 ORD GBP0.0001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.80 2.12% 135.00 134.70 135.30 139.30 129.90 130.00 1,374,056 13:18:48
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 169.67M -154.51M -0.1768 -7.61 1.16B
Oxford Nanopore Technologies Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ONT. The last closing price for Oxford Nanopore Technolo... was 132.20p. Over the last year, Oxford Nanopore Technolo... shares have traded in a share price range of 86.00p to 275.00p.

Oxford Nanopore Technolo... currently has 873,871,414 shares in issue. The market capitalisation of Oxford Nanopore Technolo... is £1.16 billion. Oxford Nanopore Technolo... has a price to earnings ratio (PE ratio) of -7.61.

Oxford Nanopore Technolo... Share Discussion Threads

Showing 3176 to 3200 of 3325 messages
Chat Pages: 133  132  131  130  129  128  127  126  125  124  123  122  Older
DateSubjectAuthorDiscuss
03/5/2024
10:49
even if they crossed a threshold?
tsmith2
03/5/2024
10:44
Less than 2%, no need to inform if below reporting thresholds of 3%, for UK holders or 5% do international holders, afaik.
bamboo2
03/5/2024
10:00
bizarrely we've still not had a holding statement after the 15m trade being printed
tsmith2
03/5/2024
09:59
Thank you, assume that's a buy with TP, given current share price
tsmith2
03/5/2024
09:44
Deutsche bank target £1.90
kash_
03/5/2024
09:27
there's a news/release flag on the app but k can't see anything - anyone know/see any better?
tsmith2
03/5/2024
08:34
Vulgaris, thanks. You may of course be right, but I suspect this technology has value and the product line will continue to evolve to address the market. The chart suggests to me that capitulation is now pretty much over and buyers see the opportunity. Fortunately, no pressure on cash.
brucie5
03/5/2024
05:47
"We are confident that we can deliver underlying revenue growth of 20 to 30% in 2024 and greater than 30% in the medium term."all about COVID?
tsmith2
03/5/2024
00:33
@rec220. You may well be right. But it's a long-term speculation, which may (or may not) pay off handsomely.

How many of the 7600 are small university-project/R&D buyers vs how many are substantial regular/routine users? It's the latter who have the changing chemistry/SOP issues. Like many biotechs they had a brief bonanza from COVID, but that's now a busted flush.

vulgaris
02/5/2024
23:53
And regarding a marketable product the 7600 active customers prove you otherwise
ih_828197
02/5/2024
23:46
Sure there are a ton of companies that are profitable and from a fundamental point of view are cheap but for a company like ONT that mindset Is short-sighted (of course they Need to become profitable before the cash runway Is depleted) But If they manage to execute i believe ONT will be one of the companies to make personalized medicine finally a reality. I had the opportunity to invest in AMD in 2015 but even tho i was a strong believer in the technology i didn't because they were losing money and i felt safer investing in "cheaper" and already profitable companies, and i'm not about to make the same mistake twice
ih_828197
02/5/2024
17:55
@Brucie5. Am in the opposite position. Have taken the loss and sold out as I see better opportunities (i.e. cheap, oversold profitable companies) elsewhere. ONT technology is good, but translation to marketable product is iffy. After such a long decline trading rallies are, of course, more than likely. Good luck
vulgaris
02/5/2024
16:19
Looks like I got in right at the bottom recently. Momentum traders might arrive shortly which should provide further upside.
yasx
02/5/2024
16:10
I think you may be right.
;)

brucie5
02/5/2024
14:05
Think it's in. Have dipped toe, looking to progressively increase
tsmith2
02/5/2024
13:50
Technically this is moving to 160p next resistance. Once broken then over 200p. Buy
seball
02/5/2024
09:47
You an investor here too? Would be interested to hear your views on prospects vs share price. Bod have bought in quite heavily, but probably with one arm behind their back.
brucie5
02/5/2024
08:44
In microbiology/infection (a major user of sequencing); not in the diagnostic industry
vulgaris
02/5/2024
07:41
Vulgaris, are you in the industry?
brucie5
01/5/2024
22:47
It is good technology but - based on what their own invited speakers said at a symposium at the European Congress of Clinical Microbiology & Infectious Disease this week ---- there are still issues with read accuracy/error rates and the chemistry of kits keeps being changed, causing issues for routine SOP-guided use.
vulgaris
01/5/2024
21:18
Comparison of Illumina and ONT 'long read' offerings, of which I probably understood about 50%. But the guy seems to know whereof he speaks and seems to indicate he's minded to do another focused on ONT itself.

Which would be helpful.

brucie5
01/5/2024
19:48
Anyone help with updated broker targets here: Just googling got me-

Berenberg 3.50 reiteration April 17 (down from 5.29 last August!)
Citi 2.10 reiteration April 12 (down from 3.90 back last June!)


RBC capital 3.50 outperform November 13

What on earth do these clowns base their prices on?!!!

brucie5
01/5/2024
16:34
Humpty's back on his wall... Last visible trades at just over the £ level.
brucie5
01/5/2024
14:31
Have had the reversal looking for volume and move up
tsmith2
01/5/2024
14:05
UK venture and unis are very very strong and so lead to strong supply of tech. Although venture has been in a decline of sorts and EU catching/ caught up over the last 20 years or so. With a good supply of tech the problem then becomes how you take those forward. Nobody has an answer, but view I'm starting to form is lack of mgt. All HQs and mgt skill in tech is (generally) US based. Everywhere else is a subsid. There are good mgrs in UK, sure, but in the US you can build a top tier team who has managed a global or high growth business. Plus availability of capital etc. UK not the market for tech (for PLCs)- no funds, analysts or ecosystem. It's weak. Very weak. Negative feedback loop creates a decline. Back to the point, ONT, in my opinion is the rare exception worth backing regardless
32v31today
Chat Pages: 133  132  131  130  129  128  127  126  125  124  123  122  Older

Your Recent History

Delayed Upgrade Clock